Gss.Ax
GSS.AX operates in the Advanced Medical Equipment & Technology industry, providing specialized medical equipment and technology solutions to healthcare providers and institutions.
Business. GSS.AX operates in the Advanced Medical Equipment & Technology industry, providing specialized medical equipment and technology solutions to healthcare providers and institutions.
Analyst recommendations
1 analysts · consensus BuyAt a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
GSS.AX operates in the Advanced Medical Equipment & Technology industry, providing specialized medical equipment and technology solutions to healthcare providers and institutions.
The company's capital structure is characterized by a low debt-to-equity ratio of 0.02, indicating a conservative leverage position. However, the company is experiencing negative free cash flow of -18.6 million AUD and negative operating cash flow of -12.3 million AUD, which raises concerns about its liquidity position. The current ratio of 11.7 suggests strong short-term liquidity, but the negative net cash position after subtracting total debt is a key flag in the risk assessment.
Profitability metrics show significant underperformance relative to industry norms. The company reported a net loss of 20.1 million AUD and an operating loss of 19.9 million AUD, resulting in a return on equity of -40.13% and a return on assets of -36.8%. These figures indicate that the company is not generating returns that meet the cost of capital, which is a critical concern for investors.
The company's revenue concentration is not explicitly disclosed in the available data, but the absence of segment-specific revenue breakdowns suggests a lack of diversification in its business model. This could expose the company to higher operational risks if demand in its primary market segment declines.
Looking at the growth trajectory, the company is currently reporting negative earnings per share of -0.09 AUD, with analyst estimates projecting a slight improvement to -0.06 AUD. The mean recommendation from analysts is 2.00, indicating a "Hold" rating, with no strong buy or sell recommendations. This suggests limited near-term growth expectations and a cautious outlook from the investment community.
The risk assessment highlights medium liquidity risk and low dilution risk. The company's negative free cash flow and operating cash flow are key liquidity concerns, while the low dilution risk is supported by the absence of significant dilution sources in the available data. The risk of dilution remains low, but the company's negative cash flows could necessitate future capital raising activities.
Recent events and filings do not show any material changes in the company's operations or financial position in the latest available data. The company continues to operate in a challenging environment, with no significant new developments reported in the most recent filings or transcripts.
- The company has a conservative capital structure with a low debt-to-equity ratio but is experiencing negative cash flows.
- Profitability metrics are significantly negative, with a return on equity of -40.13% and a return on assets of -36.8%.
- The company's growth trajectory is limited, with analyst estimates projecting only a slight improvement in earnings per share.
- Liquidity risk is medium due to negative free and operating cash flows, while dilution risk remains low.
- The company's revenue concentration and lack of segment-specific data suggest potential operational risks.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | -0,06 |
| Revenue | —no estimate | —no estimate | 17,1M AUD |
| Operating income | —no estimate | —no estimate | -17,4M AUD |
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- GSS.AX Market data — financials · 2026-05-28
- Genetic Signatures Ltd Market data — analyst estimates · 2026-05-28